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Six weeks’ sebacic acid supplementation improves fasting
plasma glucose, HbA1c and glucose tolerance in db/db mice
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Aim: To investigate the impact of chronic ingestion of sebacic acid (SA), a 10-carbon medium-chain dicarboxylic acid, on glycaemic control in
a mouse model of type 2 diabetes (T2D).
Methods: Three groups of 15 db/db mice were fed for 6 weeks either a chow diet (Ctrl) or a chow diet supplemented with 1.5 or 15%
(SA1.5% and SA15%, respectively) energy from SA. Fasting glycaemia was measured once a week and HbA1c before and after supplementation.
An oral glucose tolerance test (OGTT) was performed at the end of the supplementation. Gene expression was determined by transcriptomic
analysis on the liver of the Ctrl and SA15% groups.
Results: After 42 days of supplementation, fasting glycaemia and HbA1c were ∼70 and 25% lower in the SA15% group compared with the
other groups showing a beneﬁcial effect of SA on hyperglycaemia. During OGTT, plasma glucose area under the curve was reduced after SA15%
compared with the other groups. This effect was associated with a tendency for an improved insulin response. In the liver, Pck1 and FBP mRNA
were statistically decreased in the SA15% compared with Ctrl suggesting a reduced hepatic glucose output induced by SA.
Conclusion: Dietary supplementation of SA largely improves glycaemic control in a mouse model of T2D. This beneﬁcial effect may be due to
(i) an improved glucose-induced insulin secretion and (ii) a reduced hepatic glucose output.
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Introduction
Insulin resistance is the hallmark of type 2 diabetes (T2D) and
leads to the inability for the body to utilize glucose properly.
In diabetic patients, fasting glycaemia is increased and in
the postprandial state, insulin fails to completely suppress
hepatic glucose production (HGP). It is well established
that increased HGP, rather than decreased peripheral glucose
uptake is responsible for fasting hyperglycaemia [1–4]. Even
though the relative contribution of gluconeogenesis (GNG)
and glycogenolysis to HGP is debated in T2D, it is established
that GNG contributes to hyperglycaemia both in fasting and
postprandial states.
Sebacicacid(SA)isa10-carbonmedium-chaindicarboxylic
acid (MCDA) chemically very close to its monocarboxylic
medium-chain lipid counterpart (decano¨ ıc acid). Its caloric
content is 6.6 kcal/g and it seems to behave metabolically like
a lipid: once in the body, MCDA is, either partially β-oxidized
to suberic and adipic acids in the peroxisomes and/or to
succinic acid in the mitochondria [5,6] or directly excreted
into the urine [7,8]. SA is very rarely ingested as such because
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barely available in usual food but present in low amounts
in honey [9] and concentrations of MCDA can be increased
via ω-oxidation of ingested medium-chain monocarboxylic
acids [10–12]. Even though sebacic and dodecanedioic acids
(the dicarboxylic acid with 12 carbons) are not classiﬁed as
classical nutrients, they have been proposed as an alternative
substrate to glucose for critically ill patients and T2D because
MCDAproviderapidlyavailableenergy [13,14].Morerecently,
SA intake in a mixed meal has been shown to decrease
postprandial glycaemia and hepatic glucose output in T2D
patients [15]. Nevertheless, the mid- and long-term beneﬁts
of oral SA intake on glycaemic control are unknown. This
study wasthereforeconductedin order toevaluatethe possible
antidiabetic properties of supplemented SA and to spread light
into its mechanism of action. We compared the impact of two
doses of SA supplementation on fasting glycaemia, HbA1c,
glucose tolerance and liver gene expression in a mouse model
of T2D (db/db BKS mouse) after 6 weeks of supplementation.
Research Design and Methods
Animals, Diet and SA Supplementation
F o r t y - ﬁ v e6 – 8w e e ko l dm a l eB K S . C g - m +/+Leprdb/J db/db
mice (Charles River Laboratories, France) were housed
individually. After 2 weeks of habituation, mice were
randomized into three groups (n = 15/group) based on theirDIABETES, OBESITY AND METABOLISM original article
(i) basal plasma glucose levels after a 6-h fasting period and
(ii) body weight. Differences between groups’ median were
smaller than 1.2 mmol/l (8%) for glycaemia and 0.5 g (1%) for
body weight. The control group mice were given free access to
a chow diet (diet 3437, Kliba Nafag, Basel, Switzerland: ∼31,
11 and 58% of energy from protein, fat and carbohydrate,
respectively); 7.76 g/kg food (∼1 g/kg body weight/day) of SA
were added in the chow food for the second group (SA1.5%),
corresponding to 1.5% supplementary energy coming from
SA. The third group (SA15%) received the chow diet where
77.6 g/kg food SA were added (∼10 g/kg body weight/day),
correspondingto15%energycomingfromSA.Allanimalshad
free access to water and food all along the study.
SA was bought from Hengshui Dongfeng Chemical
(HengShui City, Hebei Province, China) and its purity was
100 ± 0.5%.
Throughout the 42-day supplementation period, body
weight, water and food intake were recorded weekly. Body
composition of each animal was measured in a conscious state
on days −1a n d3 1u s i n ga nE c h o M R I ™ 3-in-1 (Echo Medical
Systems, Houston, TX, USA). Six hours fasting glycaemia was
measured weekly and insulin concentrations were measured at
days 1, 14 and 42 during supplementation period. Oral glucose
tolerance tests (OGTTs) were conducted in overnight fasted
(15 h) mice on day 36. On day 42, 6 h fasted mice were killed
for tissue collection.
Livers were collected immediately after exsanguination
by portal puncture and ﬂash frozen in liquid nitrogen.
All procedures were approved by the cantonal veterinary
authorities (Lausanne, Switzerland) under authorization
number 2191.
Oral Glucose Tolerance Test
OGTT was performed at the end of the supplementation
period. Mice were fasted for 15 h starting at 17:00 hours. After
measuring fasting glucose concentration in blood obtained by
tail incision, using an Ascensia Elite XL glucometer (Bayer AG,
Zurich, Switzerland), animals were given a glucose solution at
1.5 g/kg (wt/BW) by oral gavage at time 0. Blood glucose was
measuredafter15,30,60and120 min.Bloodwasalsocollected
in EDTA coated tubes at 0, 15 and 60 min for insulin analyses.
Liver Biochemistry
Total lipids were extracted from 200 mg frozen liver according
toFolchet al. [16].Triglycerides(TG)wereﬁrsthydrolysedina
basicsolution(0.5NKOHinethanol)andthenmeasuredusing
a commercial enzymatic triglyceride analysis kit (PAP 150,
BioM´ erieux, Marcy l’Etoile, France). Total cholesterol (Roche
Diagnostics, Basel, Switzerland) was measured following
manufacturer’s instructions. For glycogen, ﬂash frozen liver
(50–100 mg) was incubated in 2 ml 30% KOH for 15–30 min
in a boiling water bath. After homogenization, glycogen was
precipitatedwith3 ml96%ethanolfollowedbyacentrifugation
at10 000g for10 min.Pelletswereresuspendedin1 mldistilled
waterfortheamyloglucosidasedigestion.Samples(200μl)were
incubated in 1.8 ml of lyophilized amyloglucosidase dissolved
in acetate buffer (0.2 M, pH 4.8 at a ﬁnal concentration of 10
U/ml) for 2 h at 40
◦C. The resulting glucose solution was then
measured with a Quantichrom Glucose Assay Kit (BioAssay
Systems, Hayward, CA, USA).
Plasma Biochemistry
Plasmatriglyceride(PAP150,BioM´ erieux),non-esteriﬁedfatty
acids (FAs) (Wako, Neuss, Germany), insulin (IBL, Hamburg,
Germany) and adiponectin (Millipore Corporation, Billerica,
MA,USA)levelsweremeasuredusingcommercialkits.Plasma
alanine (#DF43A) and aspartate (#DF41A) transaminases
activity were measured using the Dimension Xpand Plus
(Siemens HealthCare Diagnostics, Deerﬁeld, IL, USA). HbA1c
(#DF105) percentage was determined using the Dimension
Xpand Plus (Siemens HealthCare Diagnostics) with 100 μlo f
fresh total blood.
Gene Expression Analysis
Total RNA Extraction, Labelled-cRNA Synthesis and Hybridi-
zation. Liver tissue samples (∼10 mg wet weight) were dis-
rupted and homogenized in lysis buffer using a FastPrep
instrument and lysing tubes containing ceramic beads (MP
Biomedicals, Irvine, CA, USA). Total RNA was then extracted
and puriﬁed with the RNAdvance Tissue Kit (Agencourt,
Beverly, MA, USA) through an automated procedure on a
robotic station. After extraction, RNA quality was checked
for RNA integrity numbers ≥8 by Agilent 2100 Bioanal-
yser (Agilent Technologies, Palo Alto, CA, USA). All cRNA
targets were synthesized, labelled and puriﬁed according to
the Illumina TotalPrep RNA ampliﬁcation protocol (Applied
Biosystems/Ambion, Austin, TX, USA) through an automated
procedure originally deployed for Affymetrix sample prepa-
ration that was adapted for Illumina [17]. Brieﬂy, 200 ng of
total RNA was used to produce double-stranded cDNA, fol-
lowed by an in vitro transcription, and by cRNA labelling
with biotin. This method is based on the Eberwine T7 pro-
cedure [18]. Prior to the hybridization on the arrays, 750 ng
of biotin labelled cRNAs was added to the hybridization mix,
whichcontainedcontrololigonucleotides(suchasnegativeand
hybridization controls), hybridization buffer and water. Then,
15 μl of each hybridization mix was dispensed on the arrays.
After an overnight hybridization (16 h, 58
◦C), the arrays were
washed to remove non-hybridized material, and stained with
Streptavidin–Cy3 which bind to biotin. All samples were anal-
ysed with MouseRef-8 v1.1 Expression BeadChips (Illumina,
San Diego, CA, USA), which interrogate 24 600 transcripts.
Microarray Processing and Data Acquisition. Scanning was
performed using the BeadArray Reader (Illumina), which
provides intensity values for all transcripts, measuring the
signal emitted by the Streptavidin–Cy3 conjugates responding
to a laser excitation. Signal intensities were extracted and
summarized in the BeadStudio software (Illumina). Raw data
were expressed as absolute signal intensities.
Statistical Analysis
Data are presented as median ± standard error of the median
(s.e.median). The s.e.median was computed based on the
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robuststandarddeviation:SnofRousseeuw,pvalueswerecor-
rected for multiplicity of test (Sidak–Bonferroni procedure).
Insulinaemia, HbA1c, other plasma parameters, OGTT [time
0 and area under the curve (AUC)], liver parameters, NMR
datawereanalysedwithnon-parametrictests,thatis,Wilcoxon
tests (estimated difference by Hodges–Lehmann). The change
on HbA1c is tested against 0 for each group by Wilcoxon
signed-rank tests. The software R 2.6.1 was used to perform
the analysis [19]. For mRNA expression, quality control and
statistical analysis of microarray data were carried out with
Partek software (Partek, St. Louis, MO, USA). After quantile
normalizationandalog2transformation,qualitycontrolofthe
data was performed with a Pearson correlation matrix and a
principal component analysis on all probes to help determine
possibleoutliers.Toassesswhichtranscriptswere differentially
expressed between SA15% and control groups, a one-way anal-
ysis of variance (ANOVA) was performed, followed by a global
errorassessment(GEA) [20].TheGEAresultsinarobustmean
squarederror(MSE), whichreplacesthecurrentMSEfromthe
classical ANOVA, a new F statistic is recalculated and a robust
p value derived.
Results
Body Weight and Body Composition
After the end of the supplementation, neither body weight
(44.4 ± 0.9, 44.1 ± 1.3 and 43.5 ± 0.7 g) nor % body fat (58.4
± 0.7, 59.7 ± 0.9 and 58.7 ± 0.6% BW) was different among
groups for the Ctrl, SA1.5% and SA15% groups, respectively.
Food and Water Intake
Cumulatedfoodintakeoverthe42 dayswasreduced(p < 0.05)
in the SA15% group compared to others (513.4 ± 13, 611.3 ±
15.6 and 582.1 ± 12.2 kcal, for the SA15%,C t r la n dS A 1.5%
groups, respectively). At day 36, water intake was higher
(p < 0.001) in the Ctrl (11.9 ± 1.2 ml) and SA1.5% (10.2
± 1.5 ml) than in the SA15% group (4.0 ± 0.4 ml).
Fasting Glycaemia, Insulinaemia and HbA1c
Glycaemia evolution during supplementation is depicted in
ﬁgure 1. We observed a signiﬁcant increase in glycaemia over
the 6 weeks’ period of the trial in the non-supplemented
and SA1.5% groups. On the opposite, in the SA15% group,
fasting glycaemia plateaued at a value very close to the
presupplementation values, leading to a 40% difference
compared to the non-supplemented and the SA1.5% group
at day 42 (p < 0.01). Fasting plasma insulin concentrations
were reduced during the course of the trial without any
differences between groups: for the Ctrl, SA1.5% and SA15%
groups it decreased from 982 ± 167, 1148 ± 148 and 918
± 121 pm/l before supplementation to 145 ± 44, 184 ± 35
and 173 ± 43 pm/l after supplementation, respectively. The
long-term glucose control was also evaluated by measuring
HbA1c (Table 2). Brieﬂy, there was no difference in HbA1c
between groups before supplementation, the Control (Ctrl)
and SA1.5% groups displayed increased (∼30%) HbA1c values
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Figure 1. Fasting blood glucose measured weekly during the study after a
6-h food deprivation. Open circle: Ctrl, black diamond: SA1.5% and black
square: SA15%. ∗pv a l u e< 0.05, ∗∗pv a l u e< 0.01 as compared to control
group.
at sacriﬁce while signiﬁcant lower glycated haemoglobin was
observed in the SA15% group. Moreover, HbA1c values were
decreased inthe SA15% groupaftersupplementationcompared
to presupplementation values.
Oral Glucose Tolerance Test
To determine the effect of SA on whole-body glucose
homeostasis, we examined glucose clearance during an OGTT.
The SA15% group displayed a signiﬁcant improvement in
glucoseclearance(ﬁgure 2)resultingin∼40%reductioninarea
under the glucose curve (p < 0.01). This effect was associated
with a tendency for an improved insulin response in the SA15%
compared with the other groups. The AUCins/AUCglucose was
approximately two times higher in the SA15% group compared
withthecontrolgroupalthoughitdidnotreachedsigniﬁcance:
0.31 ± 0.1 vs. 0.14 ± 0.02 (pmol/l × 60 min) × (mmol/l ×
60 min)−1 (p = 0.057).
Liver Composition
AsshowninTable 1,higherlevelsofTGwerefoundintheliver
of SA1.5% (+12%) and SA15% (+20%) mice compared with
Ctrl, although the differences were not statistically signiﬁcant
(ns). Moreover, liver glycogen levels tended to be reduced in
SA1.5% (−25%, ns) and SA15% mice (−55%, ns) compared
with Ctrl. Liver cholesterol concentrations were not different
between all groups.
Plasma Results at Sacriﬁce
AsshowninTable 2,weobservedsigniﬁcantlydecreasedNEFA
concentrations after 15% supplementation. Neither plasma
TG nor adiponectin concentrations were changed after SA
supplementation. Total ketone bodies (KB) and cholesterol
concentrationsweresigniﬁcantlyincreasedintheSA15% group.
PlasmaALTvalueswerenotdifferentbetweengroups,although
AST concentrationswere slightlyincreased in the SA15%,i tw a s
still in the normal range [21].
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Figure 2. Oral glucose tolerance test measurements performed at the end of the supplementation period: (A) blood glucose, (B) area under the curve
(AUC) blood glucose, (C) plasma insulin and (D) insulin AUC. Open circle: Ctrl, black diamond: SA1.5% and black square: SA15%. ∗pv a l u e< 0.05,
∗∗pv a l u e< 0.01 as compared to control group.
Table 1. Postsupplementation (sacriﬁce) fasting liver TG, glycogen and
cholesterol concentrations.
Liver content Ctrl SA1.5% SA15%
TG (mg/g tissue) 40.1 ± 4.4 45.1 ± 2.5 47.9 ± 3.1
Glycogen (mg/g tissue) 25.0 ± 3.5 19.0 ± 2.9 11.0 ± 2.1
Cholesterol (mg/g tissue) 2.8 ± 0.1 2.7 ± 0.1 3.1 ± 0.1
Data are median ± s.e.median.
SA, sebacic acid; TG, triglycerides.
Liver Gene Expression
In order to better understand the mechanism of action of
SA, we performed a transcriptomic analysis of the liver
by comparing the SA15% group to the Ctrl. Relative gene
expression values (SA15%/Ctrl) are presented as fold change
expression followed by the interval of conﬁdence at 99.9%.
The cut-off of ±30% (SA15%/Ctrl) has been chosen based
upon manufacturer’s recommendations. Genes are statistically
differentwhenp < 0.001.Amongstthe24 600genestested,288
were upregulated and 182 were downregulated. The complete
list is available in Supporting Information (Table S1) and
selected genes are presented in Table 3.
Brieﬂy, we observed a clear decrease in the expression of key
gluconeogenic genes: Pck1 and Fbp1 [0.57 (0.51–0.63) fold
and0.73(0.65–0.8)fold,respectively].Glucose-6-phosphatase
was not different between groups. For lipogenesis, only SCD1
Table 2. Fasting plasma metabolites, hormones and enzyme concentra-
tions at sacriﬁce (except HbA1c: pre- and postsupplementation).
Ctrl SA1.5% SA15%
Presupplementation
HbA1c (%)
5.3 ± 0.1 5.5 ± 0.2 5.5 ± 0.2
Postsupplementation
HbA1c (%)
7.0 ± 0.3 7.0 ± 0.4 5.2 ± 0.2∗†
NEFA (mM) 0.97 ± 0.05 0.92 ± 0.06 0.71 ± 0.07‡
TG (mM) 1.02 ± 0.05 1.06 ± 0.05 0.91 ± 0.06
Adiponectin (μg/ml) 7.40 ± 0.55 6.04 ± 0.51 6.66 ± 0.32
Total KB (μmol/l) 1295 ±188 1815 ± 356 2220 ± 237‡
Total cholesterol (mM/l) 2.23 ± 0.18 2.18 ± 0.11 2.91 ± 0.11∗
AST (U/l) 71 ± 58 0 ± 69 8 ± 5‡
ALT (U/l) 81 ± 57 7 ± 78 4 ± 7
Data are median ± s.e.median.
KB, ketone bodies; SA, sebacic acid; TG, triglycerides.
∗pv a l u e< 0.01 as compared to control group.
†Different from presupplementation.
‡pv a l u e< 0.05.
and PPARγ [1.6 (1.47–1.81) fold and 1.37 (1.23–1.52) fold,
respectively) were upregulated in the SA15% group. LPL was
increased by 1.36 (1.21–1.53) fold.
Completerawdatacanbeconsultedathttp://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?token=bhkzvuyouoqeczk&acc=
GSE21083
Volume 12 No. 12 December 2010 doi:10.1111/j.1463-1326.2010.01308.x 1123original article DIABETES, OBESITY AND METABOLISM
Table 3. Main metabolic pathways and gene expression.
Pathway Gene name Fold change (SA15%/Ctrl)
Pck1 0.57 (0.51–0.64)∗
Gluconeogenesis Fbp1 0.73 (0.66–0.8)∗
G6pc <0.3
Glycolysis Gck <0.3
GYS2 <0.3
Glycogen PyGL <0.3
Pgm <0.3
SCD1 1.63 (1.47–1.81)∗
FAS <0.3
Lipogenesis ACC <0.3
SREBP-1a <0.3
SREBP-1c <0.3
PPARγ 1.37 (1.23–1.52)∗
FABPs <0.3
Fatty acid transport FATP <0.3
CD36 <0.3
LPL 1.36 (1.21–1.53)∗
CPT I <0.3
CPT II <0.3
SCAD <0.3
MCAD <0.3
Fatty acid oxidation LCAD <0.3
VLCAD <0.3
Hadhb <0.3
Hadhsc <0.3
PPARα< 0.3
SA, sebacic acid.
∗p < 0.001 SA15% is statistically different from Ctrl group.
Discussion
The current study shows that 6 weeks’ supplementation with
the 15%energydoseofSApromotesalong-lastingstabilization
offastingglycaemiaandaclearimprovementofOGTT-induced
glycaemia both contributing to a marked reduction of HbA1c
values. At the end of the supplementation, fasting glycaemia
of the SA15% group was comparable to that of lean healthy
db/+ animals [22], while non-supplemented animals’ fasting
glycaemia increased by ∼75% during the study.
Excessive HGP is a major contributor to both fasting and
postprandial hyperglycaemia and is suppressed by insulin by
inhibiting the expression of gluconeogenic enzymes, namely
phosphoenolpyruvate carboxykinase 1 (Pck1), fructose-1,6-
bisphosphatase (Fbp1) and glucose-6-phosphatase. We were
able to show that a 15% supplementation with SA during 6
weeksdecreasedPck1andFbp1mRNAlevels(−75and−38%,
respectively). In a recent study, Gomez-Valades et al. [23] par-
tially silenced Pck1 expression by ∼50% in the liver of db/db
miceandobservedareductionoffedglycaemiaconﬁrmingthat
the downregulation of Pck1 per se in the liver only can be suf-
ﬁcient to improve glycaemia in this model of T2D. Moreover,
the phenotypes observed after SA supplementation showed
similarities with the phenotype observed by Gomez-Valades
et al. characterized by a dramatic decrease in liver glycogen, an
increase in liver TG and an improvement of glucose tolerance.
Moreover, in the current experiment, expression of Fbp1 was
also reduced by 38% and it has been shown in db/db mice that
troglitazone could exert hypoglycaemic effects only through
decreased activity of Fbp1 [24]. Moreover, key transcription
factorsofPck1andFbp1werealso(althoughnon-signiﬁcantly)
reduced—FoxO1:−30%,HNF4α:−20%andPGC1α:−25%.
The role of FoxO1 in the pathophysiology of db/db mice has
already been shown as well as the hypoglycaemic effect of its
inhibition [25].
During OGTT, glycaemia was markedly reduced (AUC
decreased by ∼40%) in the SA15% group likely due to
an improved (+∼ 30%), although non-signiﬁcant, glucose-
induced insulin secretion compared with both the SA1.5% and
control groups. Improved glucose-induced insulin secretion
is probably due to decreased gluco- and lipotoxicity on
the β cell. Indeed, beside chronically decreased glycaemia
(supported by decreased HbA1c values), we observed after
sacriﬁce thatfastingplasmaNEFA concentrationsin the SA15%
group were decreased by ∼20%. Chronically lowered plasma
NEFA concentrations, if conﬁrmed, could have participated
in parallel with decreased glycaemia to the improvement of
glucose tolerance. Improvement of glucose tolerance could
also be attributed to the relative decreased food intake
observedafterSA15% comparedwiththecontrolgroup.Thisis,
however,unlikelyasneitherbodyweightnorbodycomposition
was different between groups. The improvement of diabetes
symptoms in the SA15% group is likely associated with a
decreased loss of energy from glucose in urine. Therefore,
food intake in the SA15% group may reﬂect a more ‘normal’
situation compared with the unbalanced situation in the
control group where animals lose much energy in the urine
and consequently eat more to compensate. Similarly, the
increased water consumption, usually observed in diabetes,
was normalized in the SA15% group (4 ml/day) but not in the
control (12 ml/day) or low SA group (10 ml/day).
Even though not statistically signiﬁcant, the 56% reduction
in liver glycogen is important. Glycogen content is modulated
by blood glucose concentration and by the insulin/glucagon
plasma ratio. Although we did not measure glucagon, fasting
insulinaemia were not different between groups therefore the
chronicreductionofglycaemiawasprobablytheprimarycause
of reduced liver glycogen in our experiment. On the other
hand, during reduced GNG, liver glycogen could be used to
maintain euglycaemia.
Although no toxicity of SA has been observed in rat
and rabbit [26], the 20% increase in liver TG (although
not signiﬁcant) should not be overlooked. As none of the
adipogenicgenesexpressionwereincreased,denovolipogenesis
is unlikely to explain this increase. Recent papers proposed
interesting hypothesis for increased liver TG through PPARγ
and related target genes upregulation [27,28]. Matsusue
et al. [27] showed that liver overexpression of FSP27 lead to
hepatic steatosis by a reduced FA oxidation and a reduced
TG turnover through an unknown mechanism. In the current
experiment, we also observed increased PPARγ (∼1.4-fold),
adipsin and genes of the CIDE family (CIDE-a and FSP27;
∼1.4- and 2.1-fold increase, respectively) expression. As liver
freefattyacid(FFA) concentrationswerenotdifferentbetween
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groups (data not shown) reduced FFA oxidation is unlikely;
a reduced TG turnover would more likely explain relative
steatosis. The increased plasma KB concentrations are difﬁcult
to interpret as plasma NEFA concentrations were decreased.
This could be due to the decreased Pck1 expression through
decreased cataplerosis (the mechanism by which TCA cycle
intermediates are used) as shown by Hakimi et al. [29]. When
Pck1 is decreased, cataplerosis is also decreased; consequently
Acetyl CoA is more available for KB synthesis.
Interestingly, insulin sensitivity of rats and mice fed a high-
fatdietrichinmedium-chainFAswaspreservedinmusclesand
adiposetissuebutnotintheliver [30].Authorsalsoobservedan
approximatelysixtimesincreaseinliverTGinducedbyMCFA.
These results show that mono- or dicarboxylic medium-chain
FAs are interesting substrates for reducing insulin resistance
despite increased liver TG content.
In conclusion, after a 6 weeks’ supplementation with SA we
were able to show promising results on glucose metabolism
like decreased fasting glycaemia improved HbA1c level and
improved glucose tolerance in db/db mice. The mechanism
of action is still unclear but SA supplementation may act
synergistically at the level of glucose production by reducing
hepatic glucose output, or by improving glucose-induced
insulin secretion or peripheral insulin sensitivity. However,
additional experiments are required to address the precise
mechanism of action of SA on both glucose production and
insulin sensitivity.
Finally, medium- or long-chain di-acids are a novel class
of compounds that seems to present interesting properties for
glucose control. Indeed, another dicarboxylic acid, norbixin
(a carotenoidwith20carbon-chainlengthandusedasanatural
pigment from the achiote shrub) has been shown to increase
glucose uptake in 3T3-L1adipocyte [31]. It would be therefore
worth investigating further the promising properties of this
family of compounds.
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